TWST — Twist Bioscience Income Statement
0.000.00%
Last trade - 00:00- $1.70bn
- $1.45bn
- $312.97m
- 78
- 27
- 25
- 38
Annual income statement for Twist Bioscience, fiscal year end - September 30th, USD millions except per share, conversion factor applied.
2020 September 30th | 2021 September 30th | 2022 September 30th | 2023 September 30th | 2024 September 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 90.1 | 132 | 204 | 245 | 313 |
| Cost of Revenue | |||||
| Gross Profit | 28.7 | 51.7 | 84.2 | 89.7 | 133 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 230 | 285 | 434 | 462 | 534 |
| Operating Profit | -140 | -153 | -230 | -217 | -221 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -140 | -154 | -228 | -203 | -208 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -140 | -152 | -218 | -205 | -209 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -140 | -152 | -218 | -205 | -209 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -140 | -152 | -218 | -205 | -209 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -3.2 | -3.15 | -4.1 | -3.41 | -3.09 |